Track AngioDynamics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AngioDynamics, Inc. ANGO · Stock Open AngioDynamics, Inc. in new tab

13.59 USD
Add to portfolio
EPS
-0.88
P/B
3.30
ROE
-20.77
Beta
0.34
Target Price
20.00 USD
AngioDynamics, Inc. logo

AngioDynamics, Inc.

🧾 Earnings Recap – Q3 2026

AngioDynamics delivered another strong quarter, demonstrating sustained top-line growth and expanding profitability driven by robust performance in Med Tech and thrombectomy portfolios. The company continues to execute on strategic priorities, raising full-year guidance for the third consecutive quarter.

  • Med Tech segment, led by Auryon, achieved 19th consecutive quarter of double-digit YoY growth, supported by international expansion post-CE Mark.
  • Thrombectomy portfolio (AlphaVac and AngioVac) grew approximately 18% YoY, with AlphaVac showing record sequential revenue increase and positive clinical adoption.
  • NanoKnife saw notable growth in disposables and capital, with expanded European indications and a favorable CMS CPT 1 code rollout bolstering market access.
  • The company reaffirmed its strategic focus on large, high-margin markets amid macro uncertainties, leveraging innovation and clinical milestones.
  • Full-year revenue and EBITDA guidance were raised for the third straight quarter, reflecting confidence in continued profitable growth.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateOct. 1, 2026
EPS-0.88
Book Value4.10
Price to Book3.30
Debt/Equity6.41
% Insiders12.276%
Growth
Revenue Growth0.08%
Estimates
Forward P/E-300.22
Forward EPS-0.05
Target Mean Price20.00

DCF Valuation

Tweak assumptions to recompute fair value for AngioDynamics, Inc. (ANGO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

AngioDynamics, Inc. Logo AngioDynamics, Inc. Analysis (ANGO)

United States Health Care Official Website Stock

Is AngioDynamics, Inc. a good investment? AngioDynamics, Inc. (ANGO) is currently trading at 13.59 USD. Market analysts have a consensus price target of 20.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: AngioDynamics, Inc. is expected to release its next earnings report on Oct. 1, 2026. The market consensus estimate for Forward EPS is -0.05.

Investor FAQ

Does AngioDynamics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AngioDynamics, Inc.?

AngioDynamics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Oct. 1, 2026. The company currently has a trailing EPS of -0.88.

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Exchange Ticker
NMS (United States) ANGO
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion